Polyphor is focused on developing innovative therapies for rare diseases and oncology, with a particular emphasis on inhaled antibiotics and macrocyclic compounds. One of their key products, inhaled murepavadin, is designed to target Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF) and non-CF bronchiectasis. Currently in Phase 1 clinical trials, this novel-class antibiotic aims to address chronic infections that significantly impact the health of these patients. Additionally, Polyphor has developed lonodelestat, a neutrophil elastase inhibitor, which is being explored for its potential in treating CF and other related conditions.

In the oncology space, Polyphor is advancing balixafortide, a macrocyclic CXCR4 inhibitor that has been evaluated in clinical trials involving over 500 subjects across various therapeutic indications, including solid tumors and hematologic malignancies. Despite a setback in a Phase 3 trial for metastatic breast cancer, the company remains optimistic about the drug's potential in other areas and is actively seeking partnerships to further its development. Furthermore, Polyphor's macrocycle platform encompasses a broad range of therapeutic applications, including respiratory diseases and oncology, highlighting the company's commitment to addressing unmet medical needs through innovative science and strategic collaborations.

Switzerland

Polyphor is a Swiss biopharmaceutical company leading the research and development of a new mechanism of action in solid tumors, CXCR4 inhibition, for combination treatment in oncology, using Balixafortide, an innovative molecule based on our inhouse macrocycle chemistry.Polyphor has also discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria.

Polyphor

Company Details